Kestra Medical Techs reported a 60% year-over-year revenue increase in Q1 2027 and raised its full fiscal year 2027 revenue guidance to $141 million, representing 48% growth. This positive financial performance is driven by market expansion, improved revenue cycle management, and increased in-network patient mix, despite reporting a GAAP net loss.
Kestra Medical Techs (KMTS) announced robust Q1 2027 financial results, with a significant 60% year-over-year revenue increase and an expanded gross margin. This strong performance led the company to raise its full fiscal year 2027 revenue guidance, signaling confidence in continued growth. While the company reported a GAAP net loss, the focus on revenue growth, market expansion, and strategic investments in AI and automation suggests a positive long-term outlook for the company. Traders should note the raised guidance as a key short-term catalyst, while the long-term opportunity lies in the company's ability to execute on its strategic initiatives and achieve its gross margin targets.